Skip to main content
Eisai Co., Ltd. logo

Eisai Co., Ltd. — Investor Relations & Filings

Ticker · 4523 ISIN · JP3160400002 LEI · 353800HDEE0ZYEX4QV91 T Manufacturing
Open in API
Filings indexed 76 across all filing types
Latest filing 2026-05-25 Investor Presentation
Country JP Japan
Listing T 4523

About Eisai Co., Ltd.

https://www.eisai.com/index.html

Eisai Co., Ltd. is a research-based global pharmaceutical company engaged in the discovery, development, manufacture, and marketing of prescription medicines. The company's primary business activities are concentrated in the therapeutic areas of neurology, with a significant focus on dementia-related diseases, and oncology. Guided by its core "human health care" (hhc) philosophy, Eisai prioritizes the needs of patients and their families. The company is dedicated to developing innovative and targeted treatments for challenging medical conditions and actively promotes initiatives to improve access to medicines in developing and emerging countries.

Recent filings

Filing Released Lang Actions
「経営戦略説明会」資料
Investor Presentation Classification · 95% confidence The document is a detailed slide-style management strategy presentation (“経営戦略説明会”) by Eisai, covering three-year plans, R&D pipeline, financial targets, and business strategy. It includes an agenda, named presenters (COO, CSO, CFO), and extensive strategic and financial slides, characteristic of an investor presentation rather than a formal regulatory filing or earnings release. Hence it matches the Investor Presentation category.
2026-05-25 Japanese
訂正発行登録書
Capital/Financing Update Classification · 82% confidence The document is a corrected issuance registration statement (“訂正発行登録書”) submitted to the Kanto Finance Bureau concerning the registration of a bond issuance (corporate debt). This relates directly to the company’s financing activity (bond issuance), fitting the Capital/Financing Update category rather than a share issuance or other report type.
2026-05-15 Japanese
臨時報告書
Transaction in Own Shares Classification · 75% confidence The document is a Japanese 臨時報告書 (Timely Report) under the Financial Instruments and Exchange Act announcing the Board’s resolution to continue its Board Incentive Plan trust by disposing treasury shares to the trust. The core content is the self‐share disposal (345,600 shares) and detailed terms of that transaction. This most closely matches the “Transaction in Own Shares” category (POS).
2026-05-15 Japanese
発行登録書（株券､社債券等）
Regulatory Filings Classification · 85% confidence The document is titled “発行登録書（株券、社債券等）” and is a formal registration statement filed with the Kanto Local Finance Bureau under Japan’s Financial Instruments and Exchange Act. It details the issuance registration number, the types of securities to be issued (corporate bonds), issuance periods, amounts, and references to prospectus disclosure documents. It is neither an annual or interim report, earnings release, nor a management/board change notice, nor a proxy, capital markets announcement in the sense of a high‐level financing update. It is a legal filing under securities regulations and falls into the miscellaneous regulatory filings category. Therefore, it is classified as a Regulatory Filing (RNS).
2026-03-31 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is titled 'Confirmation Letter' (確認書) and is submitted under Article 24-5-2, Paragraph 1 of the Financial Instruments and Exchange Act. It serves as an officer certification by the CEO and CFO confirming the accuracy of the contents of the semi-annual report. According to the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a specific report type, should be classified as Regulatory Filings (RNS). H1 114
2025-11-12 Japanese
半期報告書－第114期(2025/04/01－2026/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, management discussion and analysis (MDA), and business performance metrics for the interim period (April 1, 2025, to September 30, 2025). As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report. H1 2026
2025-11-12 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.